Supergen (SUPG) provided an update on MP-529, a very selective Aurora A inhibitor. In addition to MP-529, Supergen also revealed data pertaining to a an Axl inhibitor (SGI-AXL-277), and Pim and Plk inhibitors.
SUPG has an interesting selection of targets. Pim, Plk, and Axl aren't yet of wide interest, meaning that SUPG is taking on enormous target biology risk in addition to the native chemistry/drug development risk.
SUPG is valued at ~$275M, with cash on hand of ~$75M.
Monday, November 13, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment